Global Custom Market Research Reports Provider Company

phone

Argos Therapeutics Inc (ARGS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Published Date: 11 Apr 2018
  • Number of Pages: 56
  • Category: Pharmaceuticals
  • Country: United States of America
Summary

Argos Therapeutics Inc (Argos) is a biopharmaceutical company that develops and commercializes immunotherapies for the treatment of infectious diseases and cancer. The company develops a pipeline of products based on its proprietary Arcelis technology platform. Its Arcelis-based immunotherapies use the patients dendritic cells to activate an immune response specific to the patients disease. Argos also offers AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. The company use biology of dendritic cells to develop novel technologies with applications for organ and tissue transplantation and inflammatory and the treatment of autoimmune disorders. Argos is headquartered in Durham, North Carolina, the US.

Argos Therapeutics Inc (ARGS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons To Buy


Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Publisher Name : GlobalData

3
List of Tables 5
List of Figures 5
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Argos Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Argos Therapeutics Raises US$60 Million In Series E Financing 13
Argos Therapeutics Raises US$16 Million In Venture Financing 16
Argos Therapeutics Raises US$25 Million In Series D Financing 17
Partnerships 19
Argos Therapeutics Enters into Research Agreement with Personalis 19
Invetech Enters into Agreement with Argos Therapeutics 20
Licensing Agreements 21
Argos Therapeutics to Enter into Option Agreement with Pharmstandard and Actigen 21
Argos Therapeutics Enters into Licensing Agreement with Lummy HK 22
Argos Enters into Licensing Agreement with Medinet 23
Pharmstandard Enters into Licensing Agreement with Argos Therapeutics 24
Green Cross Enters into Licensing Agreement with Argos Therapeutics 25
Equity Offering 27
Argos Therapeutics to Raise USD6.3 Million in Public Offering of Shares 27
Argos Therapeutics to Raise USD1.5 Million in Private Placement of Shares 28
Argos Therapeutics Plans to Raise Funds through Private Placement of Shares 29
Argos Therapeutics to Raise Funds through Private Placement of Shares 30
Argos Therapeutics Raises USD5.5 Million in Public Offering of Shares 31
Argos Therapeutics Raises USD50 Million in Public Offering of Shares and Warrants 32
Argos Therapeutics Plans to Raise up to USD124 Million in Public Offering of Shares 34
Argos Therapeutics Raises USD29.8 Million in Second Tranche of Private Placement of Shares and Warrants 35
Argos Therapeutics Plans to Raise up to USD36 Million in Public Offering of Shares 37
Argos Therapeutics Raises USD20 Million in First Tranche Private Placement of Shares and Warrants 38
Argos Therapeutics Completes IPO For USD49.8 Million 40
Argos Therapeutics Raises USD12 Million in Private Placement of Shares and Warrants 42
Debt Offering 43
Argos Therapeutics Raises USD6 Million in Private Placement of 9.5% Convertible Promissory Notes Due 2022 43
Argos Therapeutics Inc - Key Competitors 44
Argos Therapeutics Inc - Key Employees 45
Argos Therapeutics Inc - Locations And Subsidiaries 46
Head Office 46
Recent Developments 47
Financial Announcements 47
Apr 02, 2018: Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights 47
Nov 09, 2017: Argos Reports Third Quarter 2017 Financial Results and Operational Highlights 50
Aug 09, 2017: Argos Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights 52
Corporate Communications 54
Sep 26, 2017: Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors 54
Other Significant Developments 55
Nov 28, 2017: Argos Provides Financial Update 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List Of Tables

List of Tables
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Argos Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Argos Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Argos Therapeutics Raises US$60 Million In Series E Financing 13
Argos Therapeutics Raises US$16 Million In Venture Financing 16
Argos Therapeutics Raises US$25 Million In Series D Financing 17
Argos Therapeutics Enters into Research Agreement with Personalis 19
Invetech Enters into Agreement with Argos Therapeutics 20
Argos Therapeutics to Enter into Option Agreement with Pharmstandard and Actigen 21
Argos Therapeutics Enters into Licensing Agreement with Lummy HK 22
Argos Enters into Licensing Agreement with Medinet 23
Pharmstandard Enters into Licensing Agreement with Argos Therapeutics 24
Green Cross Enters into Licensing Agreement with Argos Therapeutics 25
Argos Therapeutics to Raise USD6.3 Million in Public Offering of Shares 27
Argos Therapeutics to Raise USD1.5 Million in Private Placement of Shares 28
Argos Therapeutics Plans to Raise Funds through Private Placement of Shares 29
Argos Therapeutics to Raise Funds through Private Placement of Shares 30
Argos Therapeutics Raises USD5.5 Million in Public Offering of Shares 31
Argos Therapeutics Raises USD50 Million in Public Offering of Shares and Warrants 32
Argos Therapeutics Plans to Raise up to USD124 Million in Public Offering of Shares 34
Argos Therapeutics Raises USD29.8 Million in Second Tranche of Private Placement of Shares and Warrants 35
Argos Therapeutics Plans to Raise up to USD36 Million in Public Offering of Shares 37
Argos Therapeutics Raises USD20 Million in First Tranche Private Placement of Shares and Warrants 38
Argos Therapeutics Completes IPO For USD49.8 Million 40
Argos Therapeutics Raises USD12 Million in Private Placement of Shares and Warrants 42
Argos Therapeutics Raises USD6 Million in Private Placement of 9.5% Convertible Promissory Notes Due 2022 43
Argos Therapeutics Inc, Key Competitors 44
Argos Therapeutics Inc, Key Employees 45

List Of Figures

List of Figures
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Physiomics plc (Physiomics) is a computational systems biology services company. It is involved in developing outsourced systems and computational systems biology models for predicting and understanding cancer drug efficacy from

View Report

Pharmstandard develops, manufactures and distributes pharmaceutical products. The company offers prescription pharmaceuticals and over-the drug (OTC) pharmaceuticals. It also provides active pharmaceutical ingredients and contract manufacturing services. Pharmstandards product portfolio

View Report

Orexigen Therapeutics Inc (Orexigen) is a biopharmaceutical company which develops and commercializes indications for the treatment of obesity. Its lead product, Contrave (naltrexone HCl / bupropion HCl prolonged release) is

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports